Cumberland Pharmaceuticals Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 11.41 million compared to USD 8.07 million a year ago. Net loss was USD 0.408639 million compared to USD 1.06 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.1 a year ago. Diluted loss per share from continuing operations was USD 0.03 compared to USD 0.1 a year ago. Basic loss per share was USD 0.03 compared to USD 0.07 a year ago. Diluted loss per share was USD 0.03 compared to USD 0.07 a year ago.
For the nine months, sales was USD 32.89 million compared to USD 27.67 million a year ago. Net loss was USD 3.13 million compared to net income of USD 0.34011 million a year ago. Basic loss per share from continuing operations was USD 0.21 compared to USD 0.08 a year ago. Diluted loss per share from continuing operations was USD 0.21 compared to USD 0.08 a year ago. Basic loss per share was USD 0.21 compared to basic earnings per share of USD 0.02 a year ago. Diluted loss per share was USD 0.21 compared to diluted earnings per share of USD 0.02 a year ago.